Leukemia. 2018 Mar 23. doi: 10.1038/s41375-018-0108-y Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA Abstract Chromosomal rearrangements that […]
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Leukemia. 2018 Jul;32(7):1561-1566. doi: 10.1038/s41375-018-0017-0. Epub 2018 Feb 2 Pawlyn C, Loehr A, Ashby C, Tytarenko R, Deshpande S, Sun J, Fedorchak K, Mughal T, Davies FE, Walker BA, Morgan GJ Abstract PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of […]
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
Received: 27 December 2016 | Accepted: 13 January 2017 | Published: 24 February 2017 | DOI: https://doi.org/10.1038/bcj.2017.12 Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Stewart D, Rasche L, Bauer M, Ashby C, Peterson EA, Ali S, Ross J, Miller VA, Stephens P, […]